🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
Study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression.
Study finds that high-dose psilocybin produced large decreases in measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Azul Journey Center will be guided by deeply experienced plant medicine elders of ancient cultural lineage who will assist in building the program’s vision, operations and protocols
The completed equity investment strengthens ties between MINDCURE and ATMA.
CATALYST Presents Foundation (“CATALYST”), an Alberta-based not-for-profit event company focused on advancing the psychedelic medicine movement in Canada, announced the second annual CATALYST Summit 2021, Canada’s largest conference in the psychedelic medicine arena.
Copyright © 2023 ATMA
